{
    "Trade/Device Name(s)": [
        "LIAISON Lyme IgG",
        "LIAISON Lyme IgG Control Set",
        "LIAISON Lyme Total Antibody Plus"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K202574",
    "Predicate Device Reference 510(k) Number(s)": [
        "K895292",
        "K191398"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR",
        "QCH"
    ],
    "Summary Letter Date": "September 2, 2020",
    "Summary Letter Received Date": "September 4, 2020",
    "Submission Date": "September 1, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema Pallidum Treponemal Test Reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgG antibodies to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum separator tube",
        "K2-EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LIAISON XL Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay (CLIA)",
        "Indirect chemiluminescence immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Reagent",
        "Analyzer"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON Lyme IgG assay using CLIA technology for qualitative detection of IgG antibodies to Borrelia burgdorferi in human serum and plasma",
    "Indications for Use Summary": "Qualitative detection of IgG antibodies to Borrelia burgdorferi in serum and plasma from patients with signs and symptoms of or suspected Lyme disease, for use with LIAISON XL Analyzer; may be used as a confirmatory test in modified two-tier testing with LIAISON Lyme Total Antibody Plus assay",
    "fda_folder": "Microbiology"
}